Related Experiment Video
Updated: May 24, 2026
06:51
Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Antibody therapy for acute lymphoblastic leukemia
Craig A Portell1, Anjali S Advani
1Division of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA. portelc@ccf.org
Current Hematologic Malignancy Reports
|March 17, 2012
Summary
Despite advances in chemotherapy, acute lymphoblastic leukemia (ALL) patients often relapse. Antigen-directed therapies targeting CD20, CD22, CD52, and CD19 offer promising new strategies for relapsed ALL.
Area of Science:
- Hematology
- Oncology
- Immunotherapy
Background:
- Acute lymphoblastic leukemia (ALL) is often curable with chemotherapy, but relapse remains a significant challenge.
- Treatment options for relapsed ALL are limited, with few advances in recent decades.
- Antigen-directed therapies show promise in complementing traditional chemotherapy for ALL.
Purpose of the Study:
- To review four key antigens in ALL: CD20, CD22, CD52, and CD19.
- To evaluate therapeutic strategies targeting these antigens in ALL.
- To assess clinical and preclinical data for novel ALL treatments.
Main Methods:
- Review of clinical and preclinical data on antigen-directed therapies for ALL.
- Evaluation of targeted agents including rituximab, epratuzumab, inotuzumab ozogamicin, alemtuzumab, and blinatumomab.
- Assessment of chimeric antigen receptor (CAR)-T cell therapy in ALL.
Main Results:
- Antigen-directed therapies have demonstrated encouraging results in managing relapsed ALL.
- Specific agents targeting CD20, CD22, CD52, and CD19 are under investigation.
- CAR-T cell therapy represents a novel approach for ALL treatment.
Conclusions:
- Targeting specific antigens on ALL cells offers a promising avenue for overcoming treatment resistance.
- Further research into antigen-directed therapies and CAR-T cells is crucial for improving outcomes in relapsed ALL.
- These novel strategies have the potential to significantly advance the management of acute lymphoblastic leukemia.
More Related Videos
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
Related Concept Videos
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:26Antibody Actions
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
01:24B Cell Activation and Differentiation
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.